Closing VRUS (Pharmasset) outperform
Pharmasset is now up 30% over recent lows with the same fundamentals. I'm not seeing any short term catalysts with no significant data expected for the remainder of the year. I see the current upward move as high tide in a range-bound stock and expect a pullback to the 15-16 range before long. In general I try to avoid picks that go against my long-term prospects for the company so I won't drop a red thumb. But I'll be back in below 16 for sure.